Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...

During Tuesday’s Google I/O keynote, Demis Hassabis, the CEO of Google DeepMind, proclaimed that we are currently “standing ...

Microsoft exposes a cryptojacking campaign using SEO poisoning and ScreenConnect to target high-performance PCs, with ...

Recursion Pharmaceuticals exceeded EPS expectations by 15.38%. The company reported a significant revenue shortfall, missing forecasts by 60.26%. Pre-market stock price fell 1.84% amid broader biotech ...

EPS exceeded forecasts by 15.38%, reflecting effective cost management. Revenue missed expectations by 60.26%, raising concerns about growth prospects. The stock price fell by 5.34% in pre-market ...

In The Lancet in 1971, Julian Tudor Hart gave medicine one of its most important insights: the availability of medical care ...

UIUC and Stanford's RecursiveMAS lets AI agents collaborate in embedding space instead of text, cutting token usage by 75% ...

Spam calls aren’t just annoying, but they keep coming back and can escalate. You block one number, and another shows up. It may look local, familiar, and even seem legitimate at first glance. That’s ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...

A federal judge has ruled Alabama's use of nitrogen gas to carry out executions does not violate the U.S. Constitution. U.S.

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...